Advanced in D-Plus Hemolytic Uremic Syndrome

Pilar Z. Aunon

Madrid, MD, ES 
Advanced in D-Plus Hemolytic Uremic Syndrome
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Pilar Aunon practices in Madrid, Spain. Aunon is rated as an Advanced expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. Their top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Kidney Transplant.

Their clinical research consists of co-authoring 17 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of D-Plus Hemolytic Uremic Syndrome.

Locations

Madrid, MD, Spain
Other Locations
La Paz, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
View 1 Less Clinical Trial

17 Total Publications

Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.
Journal: Journal of the American Society of Nephrology : JASN
Published: June 16, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Aunon's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile